11-12-04

PATENT 671302-2007

Ifn

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

: Sugamura et al.

Serial No.

10/810,527

For

NON-HUMAN MAMMAL MODEL OF AUTOIMMUNE

DISEASE HAVING OX40L GENE TRANSFERRED

**THEREINTO** 

Filed

March 24, 2004

Examiner

TBA

Art Unit

1614

745 Fifth Avenue New York, NY 10151

**EXPRESS MAIL** 

Mailing Label Number:

EV 206805205 US

Date of Deposit:

November 10, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

## **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicants respectfully direct the Examiner's attention to the documents listed on the accompanying PTO-1449 form, and which are enclosed herewith.

The Information Disclosure Statement submitted herewith is being filed before the mailing date of a first Office Action on the merits. Accordingly, it is believed that no fee is required. However, the Commissioner is authorized to charge any additional fee, or to credit any overpayment in fees, to Deposit Account No. 50-0320.

-1- 00228756

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

Consideration of this Information Disclosure Statement is respectfully requested.

Applicants respectfully request that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

Attorneys for Applicants

By:

Thomas J. Kowals

Reg. No. 32,147

Angela M. Collison Reg. No. 51,107

Tel. No. (212) 588-0800

-2- 00228756

								Sheet 1 of 1	
Based on Form	PTO-1449			ATTY. DOCKET NO. 671302-2007		SERIAL NO. 10/810,52 i			
(3/90)									
/0	CIST OF	REFERENCES CITED BY APPL	ICANT	APPLICANT					
(Use several sheets if necessary)				Sugamura ET AL.					
				FILING DATE	FILING DATE GROUP				
				March 26, 200	4	1614			
ARM LT	PADENTE		U.S. P	ATENT DOCUMENTS					
EXAMINER INITIAL	NER DOCUMENT NUMBER DATE		DATE	NAME CLASS		SUBCLASS	FILING DATE IF APPROPRIATE		
	·		FOREIG)	N PATENT DOCUMENTS		···•	L		
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	
_							1	<u> </u>	
· ·									
•									
				,					
	l	ОТ	THER PRIOR ART (Inclu	ding Author, Title, Date, Pertinent Page	es, Etc.)		4		
	AA		Brocker et al. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells in B follicles (1999) Eur. J. Immunol.29: 1610-1616						
	AB	Ndhlovu et al. C autoimmune en	Ndhlovu et al. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis (2001) J. Immunol.167: 2991-2999						
	AC	amelioration of	Higgins. Regulation of T cell activation <i>in vitro</i> and <i>in vivo</i> by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with and OX40-IgG fusion protein but not with an OX40 ligand-IgG fusion protein (1999) J. Immunol.162: 486-493						
EXAMINER				DATE CONSIDERED					
		erence considered, whether or not of and not considered. Include cop		with MPEP 609. Draw line through ommunication to applicant.					